Teachers Advisors LLC raised its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 4.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 183,485 shares of the medical research company’s stock after buying an additional 8,221 shares during the period. Teachers Advisors LLC’s holdings in Exact Sciences Corporation were worth $4,334,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Eqis Capital Management Inc. acquired a new stake in Exact Sciences Corporation during the first quarter valued at $201,000. Ameritas Investment Partners Inc. raised its stake in shares of Exact Sciences Corporation by 455.0% in the first quarter. Ameritas Investment Partners Inc. now owns 9,129 shares of the medical research company’s stock valued at $216,000 after buying an additional 7,484 shares during the last quarter. Lincoln National Corp purchased a new stake in shares of Exact Sciences Corporation during the first quarter valued at approximately $221,000. Prudential Financial Inc. raised its stake in shares of Exact Sciences Corporation by 3.0% in the first quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock valued at $263,000 after buying an additional 320 shares during the last quarter. Finally, Affinity Investment Advisors LLC purchased a new stake in shares of Exact Sciences Corporation during the first quarter valued at approximately $297,000. Hedge funds and other institutional investors own 84.86% of the company’s stock.

Exact Sciences Corporation (EXAS) opened at 38.7061 on Monday. The stock has a 50 day moving average of $36.51 and a 200 day moving average of $27.90. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $42.18. The company’s market capitalization is $4.61 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The firm had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. On average, equities research analysts predict that Exact Sciences Corporation will post ($1.18) EPS for the current year.

WARNING: “Teachers Advisors LLC Increases Stake in Exact Sciences Corporation (NASDAQ:EXAS)” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/07/teachers-advisors-llc-increases-stake-in-exact-sciences-corporation-nasdaqexas.html.

Several equities research analysts have commented on EXAS shares. Vetr lowered shares of Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 price target on the stock. in a research note on Wednesday, July 12th. Canaccord Genuity raised their price target on shares of Exact Sciences Corporation from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. Zacks Investment Research upgraded shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research note on Tuesday, June 27th. Roth Capital raised their price target on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) set a $33.00 price target on shares of Exact Sciences Corporation and gave the company a “neutral” rating in a research note on Monday, May 1st. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $40.51.

In other news, SVP D Scott Coward sold 1,987 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the transaction, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jeffrey Thomas Elliott sold 5,846 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $39.41, for a total transaction of $230,390.86. Following the completion of the transaction, the chief financial officer now directly owns 19,861 shares in the company, valued at $782,722.01. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.